NanoCarrier Co., Ltd. (4571.T)
JPY 150.0
(-1.96%)
JPY 150.0
(-1.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.64 Billion JPY | 7.77% |
| 2022 | 1.53 Billion JPY | -2.45% |
| 2021 | 1.56 Billion JPY | 388.91% |
| 2020 | 320.99 Million JPY | 82.8% |
| 2019 | 175.59 Million JPY | -93.47% |
| 2018 | 2.68 Billion JPY | -9.33% |
| 2017 | 2.96 Billion JPY | 3.25% |
| 2016 | 2.87 Billion JPY | -11.83% |
| 2015 | 3.25 Billion JPY | 1512.42% |
| 2014 | 202.03 Million JPY | -72.83% |
| 2013 | 743.51 Million JPY | -38.3% |
| 2012 | 1.2 Billion JPY | -33.2% |
| 2011 | 1.8 Billion JPY | 852.88% |
| 2010 | 189.31 Million JPY | 56.61% |
| 2009 | 120.88 Million JPY | 70.05% |
| 2008 | 71.08 Million JPY | -47.9% |
| 2007 | 136.43 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.64 Billion JPY | -0.54% |
| 2023 Q3 | 1.69 Billion JPY | 2.73% |
| 2023 FY | 1.64 Billion JPY | 7.77% |
| 2023 Q4 | 1.64 Billion JPY | -2.51% |
| 2023 Q1 | 1.65 Billion JPY | 7.95% |
| 2023 Q2 | 1.64 Billion JPY | -0.32% |
| 2022 Q4 | 1.53 Billion JPY | -8.05% |
| 2022 Q3 | 1.66 Billion JPY | 2.72% |
| 2022 FY | 1.53 Billion JPY | -2.45% |
| 2022 Q1 | 1.46 Billion JPY | -6.79% |
| 2022 Q2 | 1.62 Billion JPY | 10.81% |
| 2021 Q2 | 1.6 Billion JPY | 7.83% |
| 2021 Q4 | 1.56 Billion JPY | 0.69% |
| 2021 FY | 1.56 Billion JPY | 388.91% |
| 2021 Q1 | 1.48 Billion JPY | 364.08% |
| 2021 Q3 | 1.55 Billion JPY | -2.97% |
| 2020 FY | 320.99 Million JPY | 82.8% |
| 2020 Q1 | 194.29 Million JPY | 10.65% |
| 2020 Q2 | 249.07 Million JPY | 28.19% |
| 2020 Q3 | 254.66 Million JPY | 2.24% |
| 2020 Q4 | 320.99 Million JPY | 26.05% |
| 2019 Q1 | 943.02 Million JPY | -64.93% |
| 2019 Q3 | 176.79 Million JPY | 10.95% |
| 2019 Q4 | 175.59 Million JPY | -0.68% |
| 2019 FY | 175.59 Million JPY | -93.47% |
| 2019 Q2 | 159.33 Million JPY | -83.1% |
| 2018 Q1 | 2.93 Billion JPY | -1.16% |
| 2018 Q3 | 2.75 Billion JPY | -6.82% |
| 2018 Q4 | 2.68 Billion JPY | -2.42% |
| 2018 FY | 2.68 Billion JPY | -9.33% |
| 2018 Q2 | 2.95 Billion JPY | 0.89% |
| 2017 Q2 | 2.9 Billion JPY | -9.22% |
| 2017 Q4 | 2.96 Billion JPY | -5.13% |
| 2017 FY | 2.96 Billion JPY | 3.25% |
| 2017 Q1 | 3.2 Billion JPY | 11.42% |
| 2017 Q3 | 3.12 Billion JPY | 7.58% |
| 2016 Q3 | 2.79 Billion JPY | 0.16% |
| 2016 FY | 2.87 Billion JPY | -11.83% |
| 2016 Q1 | 2.73 Billion JPY | -15.91% |
| 2016 Q4 | 2.87 Billion JPY | 2.88% |
| 2016 Q2 | 2.78 Billion JPY | 1.76% |
| 2015 Q2 | 215.39 Million JPY | -8.89% |
| 2015 Q1 | 236.41 Million JPY | 17.02% |
| 2015 FY | 3.25 Billion JPY | 1512.42% |
| 2015 Q3 | 3.92 Billion JPY | 1723.3% |
| 2015 Q4 | 3.25 Billion JPY | -17.05% |
| 2014 Q4 | 202.03 Million JPY | -70.7% |
| 2014 Q3 | 689.41 Million JPY | -0.05% |
| 2014 FY | 202.03 Million JPY | -72.83% |
| 2014 Q1 | 833.19 Million JPY | 12.06% |
| 2014 Q2 | 689.73 Million JPY | -17.22% |
| 2013 Q1 | 1.2 Billion JPY | 0.22% |
| 2013 FY | 743.51 Million JPY | -38.3% |
| 2013 Q2 | 665.73 Million JPY | -44.88% |
| 2013 Q3 | 881.73 Million JPY | 32.44% |
| 2013 Q4 | 743.51 Million JPY | -15.68% |
| 2012 FY | 1.2 Billion JPY | -33.2% |
| 2012 Q1 | 1.82 Billion JPY | 1.29% |
| 2012 Q2 | 1.83 Billion JPY | 0.61% |
| 2012 Q3 | 1.76 Billion JPY | -3.97% |
| 2012 Q4 | 1.2 Billion JPY | -31.73% |
| 2011 Q4 | 1.8 Billion JPY | 2669.65% |
| 2011 Q3 | 65.13 Million JPY | -42.62% |
| 2011 Q1 | 128.56 Million JPY | -32.09% |
| 2011 FY | 1.8 Billion JPY | 852.88% |
| 2011 Q2 | 113.5 Million JPY | -11.71% |
| 2010 Q2 | 116.17 Million JPY | 13.31% |
| 2010 Q3 | 98.77 Million JPY | -14.97% |
| 2010 Q4 | 189.31 Million JPY | 91.66% |
| 2010 Q1 | 102.52 Million JPY | -15.19% |
| 2010 FY | 189.31 Million JPY | 56.61% |
| 2009 FY | 120.88 Million JPY | 70.05% |
| 2009 Q3 | 106.08 Million JPY | 0.0% |
| 2009 Q4 | 120.88 Million JPY | 13.95% |
| 2008 Q3 | 86.67 Million JPY | 0.0% |
| 2008 FY | 71.08 Million JPY | -47.9% |
| 2008 Q4 | 71.08 Million JPY | -17.99% |
| 2007 FY | 136.43 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 49.186% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -2501.899% |
| GNI Group Ltd. | 26.34 Billion JPY | 93.737% |
| Linical Co., Ltd. | 10.3 Billion JPY | 83.989% |
| Trans Genic Inc. | 3.81 Billion JPY | 56.725% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -179.546% |
| Soiken Holdings Inc. | 697.02 Million JPY | -136.705% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 45.381% |
| AnGes, Inc. | 2.78 Billion JPY | 40.851% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -221.236% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 98.175% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -367.032% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -249.29% |
| CanBas Co., Ltd. | 91.98 Million JPY | -1693.593% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | -50.867% |
| RaQualia Pharma Inc. | 809.83 Million JPY | -103.733% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -177.885% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 61.216% |
| PeptiDream Inc. | 29.11 Billion JPY | 94.333% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -191.243% |
| Ribomic Inc. | 155.8 Million JPY | -958.918% |
| SanBio Company Limited | 2.25 Billion JPY | 26.831% |
| Healios K.K. | 11.28 Billion JPY | 85.381% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -556.623% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -347.125% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -583.193% |
| StemRIM | 187 Million JPY | -782.294% |
| CellSource Co., Ltd. | 677.73 Million JPY | -143.44% |
| FunPep Company Limited | 189.32 Million JPY | -771.464% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -176.384% |
| Stella Pharma Corporation | 1.44 Billion JPY | -14.289% |
| TMS Co., Ltd. | 97.68 Million JPY | -1588.921% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -1703.277% |
| Cuorips Inc. | 200.96 Million JPY | -721.0% |
| K Pharma,Inc. | 209.13 Million JPY | -688.915% |
| Takara Bio Inc. | 11.42 Billion JPY | 85.553% |
| ReproCELL Incorporated | 741.03 Million JPY | -122.648% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | -79.783% |
| StemCell Institute Inc. | 3.85 Billion JPY | 57.151% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | -81.62% |
| CellSeed Inc. | 301.04 Million JPY | -448.051% |